

Anti-IL-13 Antibody (Cendakimab)

Introduction

Cendakimab (RPC4046; ABT 308; CC-93538) is a selective, humanized recombinant monoclonal antibody against IL-13. Cendakimab has high affinity and potency for human wild-type and variant IL-13 and blocks the binding of IL-13 to IL-13R α 1 and IL-13R α 2 with IC₅₀ of 352 pM and 631 pM, respectively, as determined by ELISA. Cendakimab recognizes wild-type human IL-13 and the common polymorphic variant R110Q with binding potencies of 52 pM and 50 pM, respectively. Cendakimab has the potential to be used in IL-13-related allergic/inflammatory diseases such as asthma and eosinophilic esophagitis.

Product parameters

Alternative Names	ABT-308, 13C5.5, RPC4046
Target Accession	P35225
Target	IL-13
CAS number	2151032-62-9
Molecular Weight	145 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 μ M filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years

Note

1. This product is for scientific research use only.



APEx BIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

